Azienda Sanitaria Locale Di Taranto
- Address
- lock Available on a paid plan
Azienda Sanitaria Locale Di Taranto - Oncology & Hematology Research Center
Azienda Sanitaria Locale Di Taranto is a clinical research institution with demonstrated expertise in oncology and pediatric hematology. The center participates in advanced international collaborative treatment protocols, focusing on innovative immunotherapy approaches and targeted molecular therapies for both adult and pediatric populations.
- Non-small cell lung cancer (NSCLC) immunotherapy trials, including maintenance pembrolizumab and combination therapies for advanced disease
- Pediatric hematologic disorders, including acute lymphoblastic leukemia (ALL) treatment protocols
- Rare disease research in Langerhans Cell Histiocytosis with multi-system involvement
The center demonstrates particular strength in precision oncology with trials targeting specific genetic mutations such as KRAS G12C in lung cancer. Their involvement in pediatric studies reflects commitment to multi-center collaborative research, implementing complex treatment protocols that combine chemotherapy, immunotherapy, and novel targeted agents. The facility's research portfolio spans from locally advanced to metastatic disease stages, with emphasis on improving overall survival and reducing long-term sequelae in vulnerable patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 107 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 106 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Di Taranto
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene | Bial R&D Investments S.A. | Phase II | Not Recruiting | Jul 2023 | Apr 2026 |
IMP list
lock Showing 1 of 107 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 6 | Unknown | 2018-07-15 | 2024-10-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.